Knight Therapeutics Inc. (TSX:GUD)
11.27
-0.13 (-1.14%)
Oct 30, 2026, 4:00 PM EDT
Knight Therapeutics Employees
Knight Therapeutics had 830 employees as of December 31, 2025. The number of employees increased by 85 or 11.41% compared to the previous year. That makes Knight Therapeutics the 16,256th largest employer in the world and 259th in Canada.
Employees
830
Change (1Y)
85
Growth (1Y)
11.41%
Revenue / Employee
659.40K CAD
Profits / Employee
17.92K CAD
Market Cap
1.11B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 830 | 85 | 11.41% | 830 | 0 |
| Dec 31, 2024 | 745 | 20 | 2.76% | 745 | 0 |
| Dec 31, 2023 | 725 | 27 | 3.87% | 725 | 0 |
| Dec 31, 2022 | 698 | 38 | 5.76% | 698 | 0 |
| Dec 31, 2021 | 660 | -19 | -2.80% | 660 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Curaleaf Holdings | 5,554 |
| Green Thumb Industries | 4,900 |
| Verano Holdings | 3,800 |
| Cresco Labs | 2,900 |
| Canopy Growth | 1,128 |
| Aurora Cannabis | 1,028 |
| Vireo Growth | 612 |
| Cronos Group | 610 |
Knight Therapeutics News
- 1 day ago - Notice of Knight Therapeutics’ Third Quarter 2026 Results Conference Call - Financial Post
- 1 day ago - Notice of Knight Therapeutics' Third Quarter 2026 Results Conference Call - GlobeNewsWire
- 14 days ago - Knight Therapeutics price target raised to C$12.25 from C$11 at Stifel - TheFly
- 24 days ago - Knight Therapeutics Announces Launch of TAVALISSE® in Brazil - BNN Bloomberg
- 24 days ago - Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil - Financial Post
- 4 weeks ago - Knight Therapeutics, Kyowa Kirin enter distribution agreement for POTELIGEO - TheFly
- 4 weeks ago - Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America - Business Wire
- 4 weeks ago - Knight Therapeutics signs exclusive distribution agreement with Kyowa Kirin - TheFly